6-oxo-PGF1 alpha -a new tumour marker for tumours in the maxillo-facial region.
The diagnosis of secondary or recurrent tumour growth after operations on primary maxillo-facial tumours is still only possible at a late stage. On the other hand, the prostaglandins of the E series assume an important role in connection with tumour growth. The present investigation succeeded for the first time in detecting an increase in the level of 6-oxo-PGF1 alpha, the stable metabolite of PGI2, before planned radical operation in patients with maxillo-facial tumours. In the further course of the illness it was possible to establish a correlation between the plasma values and the occurrence of metastasis or recurrence of disease. These results indicate that a certain significance can be attributed to 6-oxo-PGF1 alpha as a tumour marker.
D015121:6-Ketoprostaglandin F1 alpha / Q000032:analysis / Q000378:metabolism; D005153:Facial Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D005260:Female; D006801:Humans; D007573:Jaw Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D008297:Male; D009364:Neoplasm Recurrence, Local
D015121:6-Ketoprostaglandin F1 alpha